Cytokinetics (NASDAQ: CYTK) announced the commercial launch of MYQORZO (aficamten) in Germany for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. The drug launch represents the first European market availability following European Commission approval in February 2026.

MYQORZO is a cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy. The drug received approval based on results from the SEQUOIA-HCM Phase 3 clinical trial.

In the 24-week study, patients treated with aficamten showed improved exercise capacity compared to placebo. Peak oxygen uptake increased by 1.76 mL/kg/min from baseline in the treatment group versus no change in the placebo group, with a difference of 1.74 mL/kg/min between groups.

The trial also demonstrated improvements across 10 secondary endpoints including quality of life measures, functional class improvements, and reductions in left ventricular outflow tract gradient.

MYQORZO previously received approval from the U.S. Food and Drug Administration in December 2025 for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. The drug also received approval from China's National Medical Products Administration for the same indication.

Hypertrophic cardiomyopathy affects approximately 1 in 350 individuals worldwide, with about half having the obstructive form of the disease. The condition causes abnormal thickening of heart muscle, which can block blood flow and reduce the heart's pumping function.

The information is based on a company press release statement.